Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Precision BioSciences priced a $125M offering of common stock and pre-funded warrants, expected to close Nov 6, 2026. Proceeds will fund R&D for PBGENE-HBV and PBGENE-DMD, and general corporate purposes. TD Cowen and Guggenheim Securities are joint book-running managers. According to the company, the offering is subject to customary closing conditions.
How this was made
The 30-second read
Why it matters
The offering provides needed capital but adds shares, likely causing short‑term price weakness.
Market read
A $125 M equity raise is material for a mid‑cap biotech and may move the stock in pre‑market trading.
What to watch
Potential strategic partnership or pipeline milestones not disclosed in the release.
Background
Precision BioSciences is a clinical‑stage gene‑editing company developing ARCUS‑based therapies for HBV and DMD.
Market effects
May signal increased financing activity in the gene‑editing biotech sector.
Limited to U.S. biotech investors.
Minimal global impact beyond sector.
Counterpoint
The raise could fund pivotal trials that boost long‑term valuation, offsetting short‑term dilution.
Key entities
- UnderwriterTD Cowen
Joint book‑running manager for the offering.
- UnderwriterGuggenheim Securities
Joint book‑running manager for the offering.
